April 7th, 2025
ALZpath Named 2025 BRONZE Edison Award Winner for its Proprietary pTau217 Antibody, a Key Biomarker Driving Blood-Based Alzheimer’s Disease Diagnostics
The ALZpath Antibody is Integral to Advanced Blood Tests for Early Diagnosis of Alzheimer’s Disease and is Widely Available on Research and Clinical Testing Platforms
CARLSBAD, California, April 7, 2025 — ALZpath, Inc. (ALZpath), a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced it has been honored with the Bronze Edison Best New Product award.
ALZpath’s pTau217 antibody, utilized in a wide range of commercially available blood tests, enables highly sensitive and accurate detection of pTau217, a key Alzheimer’s disease pathology biomarker, well before symptoms appear.
Prior to the availability of blood tests such as those utilizing the ALZpath pTau217 biomarker to detect Alzheimer’s disease, researchers and clinicians had to rely on positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) testing, which are invasive, costly, and require specialized equipment and expertise to administer. As a result, these tests are difficult to make available at the scale required to meet growing demands, especially as promising new treatments are reaching the market.
“It is an honor to be named as a Bronze winner by the Edison Awards for our role in addressing the growing diagnostic needs of Alzheimer’s disease patients and families,” said Mike Banville, CEO and President of ALZpath. “Our solution comes at a critical time as cases of Alzheimer’s disease and related dementias are expected to impact 153 million people worldwide by 2050 — and yet the condition remains significantly under-diagnosed. By some estimates, more than seven million Americans* with mild cognitive impairment (MCI) over age 65 don’t have a diagnosis, which means they can’t get access to the latest trials or treatments. We aim to change that by licensing our pTau217 antibody to leading diagnostic companies and labs to accelerate and expand access to an early and accurate diagnosis for as many patients as possible.”
Winning an Edison Award is a mark of distinction, honoring those who push the boundaries of innovation to solve global challenges and improve lives. Named after Thomas Edison (1847–1931), one of history’s greatest inventors, the awards celebrate forward-thinking solutions and bold ideas that shape the future. ALZpath was selected from among thousands of submissions, rigorously evaluated on Concept, Value, and Impact by the Edison Awards Steering Committee and an independent panel of experts, including senior scientists, engineers, designers and business leaders.
“The ALZpath proprietary pTau217 antibody stood out as a groundbreaking advancement in the Advancements in Neurological Treatments category, demonstrating the power of innovation to create lasting impact,” said Frank Bonafilia, Executive Director of the Edison Awards. “Our panel of judges was impressed by the ingenuity and leadership behind this innovation.”
About ALZpath
ALZpath is a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias. The novel ALZpath pTau217 antibody, integral to the most advanced, widely available blood-based tests to detect Alzheimer’s disease, is transforming its diagnosis and treatment monitoring, providing accurate and accessible tools for researchers and healthcare professionals worldwide. To help millions of patients in need, ALZpath democratizes access to its proprietary robust antibody, which is used by researchers, clinicians, and industry partners around the world to accelerate the discovery of new treatments and improve patient care.
To learn more about the company, please visit https://alzpath.bio/ and follow us on LinkedIn.
ALZpath Media Contact
Nechama Rosengarten
Nechama.Rosengarten@finnpartners.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on ALZpath’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause ALZpath’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in ALZpath’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, ALZpath assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
